Nelfinavir and lenalidomide/dexamethasone in patients with lenalidomide-refractory multiple myeloma. A phase I/II Trial (SAKK 39/10)

The antiretroviral agent nelfinavir has antimyeloma activity and can overcome resistance to bortezomib. Our phase I/II trial investigated whether adding nelfinavir to lenalidomide–dexamethasone can overcome lenalidomide resistance in lenalidomide-refractory multiple myeloma (MM). Twenty-nine patient...

Descripción completa

Detalles Bibliográficos
Autores principales: Hitz, F., Kraus, M., Pabst, T., Hess, D., Besse, L., Silzle, T., Novak, U., Seipel, K., Rondeau, S., Stüdeli, S., Vilei, S. Berardi, Samaras, P., Mey, U., Driessen, C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6711992/
https://www.ncbi.nlm.nih.gov/pubmed/31455773
http://dx.doi.org/10.1038/s41408-019-0228-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6711992/
https://www.ncbi.nlm.nih.gov/pubmed/31455773
http://dx.doi.org/10.1038/s41408-019-0228-2

Ejemplares similares